Who is a good candidate for this protocol?

Ideal candidates are children aged 1–18 years with newly diagnosed, previously untreated ALL. The protocol is suitable for standard-risk, high-risk, and very high-risk patients as determined by initial white blood cell count, genetic abnormalities (e.g., ETV6-RUNX1, BCR-ABL), and early response to therapy. Contraindications include severe organ dysfunction (e.g., heart, liver, or kidney failure), active uncontrolled infections, or prior chemotherapy. Each child undergoes a comprehensive evaluation by a pediatric oncology team to confirm eligibility.